

**To:** Egeghy, Peter[Egeghy.Peter@epa.gov]  
**Cc:** Dana Loomis[LoomisD@iarc.fr]  
**From:** Kathryn Guyton  
**Sent:** Fri 12/12/2014 2:36:55 PM  
**Subject:** Re: IARC Monograph volume 112-- revisions needed

Hi Peter!

Not to worry, there is still time to revise. You did win the prize for most assignments!

You will find Dana's reviews of Malathion Sections 1.1, 1.2, and 1.3 on IOPS (you should have received an email announcing their availability).

Don't hesitate if we can help. Thanks again for your good work!

Best regards,  
Bon weekend,  
Kate

**Kate Z. Guyton PhD DABT**

Responsible Officer, Volume 112

Monographs Section

International Agency for Research on Cancer  
150, cours Albert Thomas  
69372 Lyon Cedex 08

France  
Tel: [+33] (0)4 72 73 86 54

[Guytonk@iarc.fr](mailto:Guytonk@iarc.fr)

**From:** <Egeghy>, Peter <[Egeghy.Peter@epa.gov](mailto:Egeghy.Peter@epa.gov)>  
**Date:** Friday 12 December 2014 15:09  
**To:** Kate Guyton <[guytonk@iarc.fr](mailto:guytonk@iarc.fr)>  
**Cc:** Dana Loomis <[LoomisD@iarc.fr](mailto:LoomisD@iarc.fr)>  
**Subject:** RE: IARC Monograph volume 112-- revisions needed

Hi Kate,

Yes, as you have surmised, I misjudged the amount of time needed and got a little overwhelmed with the fifteen assignments. I apologize for the *pitoyable* state of the results. I welcome the opportunity to revise before further review. Thank you for sending the reviews and the link to the TCE example, it should prove to be very helpful.

*Merci,*

Peter

**From:** Kathryn Guyton [<mailto:GuytonK@iarc.fr>]  
**Sent:** Friday, December 12, 2014 5:44 AM  
**To:** Egeghy, Peter  
**Cc:** Dana Loomis  
**Subject:** IARC Monograph volume 112-- revisions needed  
**Importance:** High

Bonjour Peter!

I hope you are well! Thank you for your submissions of the draft Sections 1.1, 1.2. and 1.3 for monograph 112.

In reviewing these, we find that significant revision will be needed. Appended please find specific comments on the Malathion Section 1.2 Word document, as well as peer comments on Section 1.3 (also available on IOPS). These comments on Malathion apply equally to all the other drafts. Importantly, a reference list should be included for all sections.

We suggest you review these appended comments and revise the Malathion drafts accordingly, following the instructions to authors ([http://iops.iarc.fr/index.php?page=instructions&project\\_id=118&instruction\\_id=17](http://iops.iarc.fr/index.php?page=instructions&project_id=118&instruction_id=17)) and the TCE example for Sections 1.1 and 1.3 (<http://monographs.iarc.fr/ENG/Monographs/vol106/index.php> ).

We'll be happy to take a quick look at the revised Malathion drafts before you revise the others if that would facilitate your work. We will solicit peer review comments from Working Group members once all drafts are returned.

Don't hesitate with any questions. Thank you again for your efforts!

Best regards,

Kate (and Dana)

**Kate Z. Guyton PhD DABT**

Responsible Officer, Volume 112

Monographs Section

International Agency for Research on Cancer  
150, cours Albert Thomas  
69372 Lyon Cedex 08

France

Tel: [+33] (0)4 72 73 86 54

[Guytonk@iarc.fr](mailto:Guytonk@iarc.fr)

---

*This message and its attachments are strictly confidential. If you are not the intended recipient of this message, please immediately notify the sender and delete it. Since its integrity cannot be guaranteed, its content cannot involve the sender's responsibility. Any misuse, any disclosure or publication of its content, either whole or partial, is prohibited, exception made of formally approved use.*

---